U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H27N5O.2CH4O3S.H2O
Molecular Weight 683.795
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-833923 DIMESYLATE MONOHYDRATE

SMILES

O.CS(O)(=O)=O.CS(O)(=O)=O.CNCC1=CC=C(C)C(NC(=O)C2=CC=C(NC3=NC4=C(C=CC=C4)C(=N3)C5=CC=CC=C5)C=C2)=C1

InChI

InChIKey=UYMWHMMVNCGRHJ-UHFFFAOYSA-N
InChI=1S/C30H27N5O.2CH4O3S.H2O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22;2*1-5(2,3)4;/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35);2*1H3,(H,2,3,4);1H2

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923

BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. BMS-833923 is an orally bioavailable Smoothened antagonist. BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. BMS-833923 is in phase II clinical trials for the treatment of chronic myeloid leukaemia.

Originator

Curator's Comment: BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. # Exelixis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
21.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Emerging treatments and signaling pathway inhibitors.
2011 Dec
Patents

Sample Use Guides

Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Route of Administration: Oral
BMS-833923 (10 uM) decreased cell proliferation of cholangiocellular carcinoma cell line (EGI-1) up to 89.4% compared to the control.
Name Type Language
BMS-833923 DIMESYLATE MONOHYDRATE
Code English
N-(2-METHYL-5-((METHYL AMINO) METHYL) PHENYL)-4-(4-PHENYLQUINAZOLIN-2-YLAMINO) BENZAMIDE BISMESYLATE MONOHYDRATE
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C77861
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
SMS_ID
100000174998
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL3545403
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
PUBCHEM
162623676
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
FDA UNII
483ONS63WN
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY